QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.069138v1 311/2/502    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Solca, F. F. Articles by van Meel, J. C. A. Search for Related Content PubMed PubMed Citation Articles by Solca, F. F. Articles by van Meel, J. C. A.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Inhibition of Epidermal Growth Factor Receptor Activity by Two Pyrimidopyrimidine Derivatives

Departments of New Chemical Entities Pharmacology (F.S., J.C.A.v.M.) and New Biological Entities Pharmacology (A.B., K.-H.H.), Boehringer Ingelheim, Vienna, Austria; and Department of Chemical Research (E.L., G.D., F.H.), Boehringer Ingelheim, Ingelheim, Germany

Overexpression of the epidermal growth factor receptors (EGFRs) and human epidermal growth factor receptor 2 occurs frequently in human cancers and is associated with aggressive tumor behavior and poor patient prognosis. We have investigated the effects in vitro and in vivo of a new class of inhibitor molecules on the growth of several human cancer cell lines. BIBX1382 [N8-(3-chloro-4-fluoro-phenyl)-N2-(1-methyl-piperidin-4-yl)-pyrimido[5,4-d]pyrimidine-2,8-diamine] and BIBU1361 [(3-chloro-4-fluoro-phenyl)-[6-(4-diethylaminomethyl-piperidin-1yl)-pyrimido[5,4-d]pyrimidin-4-yl]-amine] are two new selective EGFR kinase inhibitors that do not block the activity of other tyrosine kinases. BIBU1361 blocked epidermal growth factor-induced phosphorylation of EGFR and also prevented downstream responses such as mitogen-activated protein kinase kinase (MAPK/extracellular signal-regulated kinase kinase) and MAPK activation in cells. In accordance with these observations thymidine incorporation into EGFR-expressing KB cells was selectively and potently inhibited by BIBX1382 and BIBU1361 with half-maximally effective doses in the nanomolar range. Oral administration of these compounds inhibited the growth of established human xenografts in athymic mice, including vulval and head and neck squamous cell carcinomas. Tumor growth inhibition by BIBX1382 coincided with reduced pEGFR and Ki-67 levels in vivo, which is in accordance with the expected effect of EGFR inhibitors. Collectively, these results show that the structural class of pyrimidopyrimidines, exemplified here by BIBX1382 and BIBU1361, represents an interesting scaffold for the design of EGFR inhibitors.

Address correspondence to: Dr. Flavio Solca, Department of NCE Pharmacology, Boehringer-Ingelheim, Austria, Dr. Boehringer-Gasse 5-11, A-1120 Vienna, Austria. E-mail: flavio.solca{at}vie.boehringer-ingelheim.com